Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Immunodeficiency Diseases 1Neoplasms 1Infections 1Epstein-Barr Virus Infections 1

Interventions

Voriconazole 2Daptomycin 2threonic acid 1telavancin 1telaprevir 1soybean oil, phospholipid emulsion 1plerixafor 1peginterferon alfa-2a 1human papillomavirus vaccine, L1 type 16, 18 1fludarabine phosphate 1Whole-Body Irradiation 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tacrolimus 1Sulfamethoxazole 1Sirolimus 1Rituximab 1Ribavirin 1Peripheral Blood Stem Cell Transplantation 1Ofloxacin 1Methotrexate 1Melphalan 1Magnesium Sulfate 1Human Papillomavirus Recombinant Vaccine nonavalent 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fluconazole 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Infections × threonic acid × Clear all
NCT02496676 2022-03-02

Magnesium Supplementation in People With XMEN Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 7 charts

Primary Immunodeficiency Diseases, Infections, Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡